Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: "Hugo Mouquet" Clear advanced filters

  • HIV-1 infection is known to impact the gut mucosa, effecting the microbiota and immune system, but early antiretroviral therapy is linked to partial reversal of this phenomena. Here the authors explore the impact of early commencement of antiretroviral therapy and show this can limit the abnormal responses of intestinal B cells associated with HIV-1 infection.

    • Cyril Planchais
    • Luis M. Molinos-Albert
    • Hugo Mouquet
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-17

  • A rare sub-population of people living with HIV-1 experience long-lasting viral remission after interrupting antiretroviral therapy and are considered post-treatment controllers. Here the authors characterise the humoral immune response to HIV-1 in a cohort of post-treatment controllers.

    • Luis M. Molinos-Albert
    • Valérie Lorin
    • Laetitia Laine
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-17

  • Broadly neutralizing antibodies (bNAbs) are promising as potential therapies targeting HIV-1 but their overall antiviral activity remains to be fully elucidated. Here the authors evaluate the ability of a panel of bNAbs to trigger antibody-dependent cellular cytotoxicity and identify the most effective antibody combinations.

    • Timothée Bruel
    • Florence Guivel-Benhassine
    • Olivier Schwartz
    ResearchOpen Access
    Nature Communications
    Volume: 7, P: 1-12

  • More than 30 years since the AIDS pandemic began, there is still no effective vaccine. But analysis of broadly acting, potent human antibodies obtained from single cells suggests a rational approach to vaccine development. See Article p.469

    • Hugo Mouquet
    • Michel C. Nussenzweig
    News & Views
    Nature
    Volume: 496, P: 441-442